Boyle Kevin S. Sr. 4
4 · ZIOPHARM ONCOLOGY INC · Filed Aug 31, 2021
Insider Transaction Report
Form 4
Boyle Kevin S. Sr.
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2021-08-30+875,000→ 875,000 total - Award
Employee Stock Option (right to buy)
2021-08-30+2,625,000→ 2,625,000 totalExercise: $1.64Exp: 2031-08-29→ Common Stock (2,625,000 underlying)
Footnotes (2)
- [F1]One-fourth of the shares vest on each of August 30, 2022, August 30, 2023, August 30, 2024 and August 30, 2025, subject to the Reporting Person's continued service through each such date.
- [F2]One-sixteenth of the shares underlying the option vest in equal quarterly installments commencing three month after 8/30/2021, subject to the Reporting Person's continued service through each such date.